Researchers at the German Center for Cardiovascular Research (DZHK) have identified a key molecule involved in a form of ...

The new Tempus software analyzes resting, non-ambulatory 12-lead ECG recordings to detect signs associated with having a low ...

A new study shows that people with a type of heart failure called HFpEF (heart failure with preserved ejection fraction) are ...

The US Food and Drug Administration (FDA) has granted 510(k) clearance for Tempus AI’s ECG-Low (ejection fraction) EF ...

A 74-year-old woman develops haemolytic anaemia and stress cardiomyopathy after a tick bite, highlighting a rare cardiac complication of babesiosis.

The drug is now approved for treating people with an LVEF of at least 40%, with or without chronic kidney disease.

Patients with overweight or obesity and heart failure with preserved ejection fraction that have unintentional weight loss have worse outcomes.

The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.

Following priority review, the FDA approved Kerendia for the treatment of patients with heart failure with left ventricular ejection fraction (LVEF) ≥40%.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

CVRx, Inc. (NASDAQ: CVRX) ('CVRx”), a commercial-stage medical device company, announced today that the Centers for Medicare ...

Bayer’s Kerendia (finerenone) has been approved by the US Food and Drug Administration (FDA) to treat heart failure (HF) patients with left ventricular ejection fraction (LVEF) of at least 40%.